Latest News- PARP (Poly ADP-ribose Polymerase) Inhibitors Market: Retail pharmacies is expected to lead the Distribution Channel segment during 2024-2028

The PARP (Poly ADP-ribose Polymerase) Inhibitors Market is being driven by Expanded application of PARP inhibitors

The PARP (Poly ADP-ribose Polymerase) Inhibitors Market is expected to grow at a CAGR of 13.25% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 5.56 billion. The PARP (Poly ADP-ribose Polymerase) inhibitors market is characterized by a significant presence of leading pharmaceutical companies, each bringing innovative therapies to the table for the treatment of various solid tumors. Notably, PARP inhibitors have demonstrated superior efficacy in addressing these types of cancers, leading to an expansion of the market pipeline. Key players in this sector, including Jiangsu Hengrui Medicine Co., Ltd., BeiGene, AbbVie Inc., and Pfizer Inc., are renowned for their robust research and development capabilities, making substantial strides in the late stages of clinical trials with promising PARP inhibitor therapies. 

Get more information on PARP (Poly ADP-ribose Polymerase) Inhibitors Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Distribution Channel
  • Retail pharmacies
  • Hospital pharmacies
  • Online pharmacies
• End-user
  • Ovarian cancer
  • Breast cancer
  • Others
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Expanded application of PARP inhibitors
• Ease of administration for treatment of various cancer indications
• Increasing patient assistance programs

However, the market also witnesses some limitations, which are as follows:

• Advent of novel therapies
• Limitations of PARP inhibitors for cancer treatment
• Trial failures of drugs

Benefits of Buying Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in PARP (Poly ADP-ribose Polymerase) Inhibitors Market Research Report

Request Free Sample

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The PARP inhibitor market encompasses Olaparib, Talazoparib, Veliparib, Rucaparib, and Niraparib, which are used primarily in the treatment of various types of cancer, including ovarian, breast, fallopian tube, and metastatic breast cancer. These anti-cancer drugs target the PARP enzyme, which plays a role in repairing single-stranded DNA breaks. BRCA gene mutations increase the need for PARP inhibitors in personalised medicine. Hospitals, homecare, and specialty clinics are key distribution channels. Clinical trials and lifecycle management are crucial for market growth. PARP inhibitors can be used in combination with checkpoint inhibitors to combat tumor resistance and improve progression-free survival. UV radiation and BRCA gene mutations can trigger the need for PARP inhibitors. PARP inhibitors are also being explored for prostate cancer and geriatric population. ADP-ribose is the substrate used by PARP enzymes, and PARP inhibitors prevent its modification, leading to increased DNA damage and cancer cell death. Single stranded DNA breaks are repaired by PARP, and PARP inhibitors hinder this repair process, making cancer cells more susceptible to chemotherapy and radiation therapy. Combination therapies using PARP inhibitors and other anti-cancer drugs are being investigated to enhance treatment efficacy.

Market Research Overview

The PARP (Poly ADP-ribose Polymerase) inhibitors market is a significant segment of the global pharmaceuticals industry, encompassing Olaparib, Talazoparib, Veliparib, and other emerging PARP inhibitors. This market is part of the broader healthcare industry, which Technavio values based on the consolidated revenue of pharmaceutical manufacturers and providers. The pharmaceuticals sector includes entities involved in R&D and production of generic and non-generic drugs, as well as veterinary medicines. Key growth drivers for the pharmaceuticals market include the increasing global population aging, with the number of individuals over 60 years projected to rise significantly. This demographic shift will fuel demand for treatments for diseases prevalent among the elderly, such as ovarian and breast cancer, including fallopian tube cancer, for which PARP inhibitors offer promising therapeutic options. In homecare settings and hospitals, PARP inhibitors will continue to gain traction as effective, targeted therapies for cancer patients.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/